| |
| |
|
| Insider
Information: |
Leonard John M. |
| Relationship: |
|
| City: |
North Chicago |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,085,175 |
|
|
Indirect Shares
|
64,888 |
|
|
| Direct
Value |
$46,223,586 |
|
|
|
Indirect Value
|
$2,608,878 |
|
|
| Total
Shares |
1,150,063 |
|
|
| Total
Value |
$48,832,464 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 91.2%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Abbvie Inc. |
ABBV |
SVP, Chief Scientific ... |
2013-03-15 |
107,320 |
2013-03-15 |
6,473 |
Premium* |
|
|
Chimerix Inc |
CMRX |
Director |
2015-08-21 |
4,000 |
2016-09-15 |
0 |
Premium* |
|
|
IQVIA Holdings Inc |
IQV |
Director |
2024-05-07 |
13,783 |
2015-03-04 |
0 |
Premium* |
|
|
Intellia Therapeutics, Inc. |
NTLA |
|
2024-03-01 |
960,072 |
2024-03-01 |
58,415 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
75 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ABBV |
Abbvie Inc. |
SVP, Chief Scientific Officer |
• – – |
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
30,360 |
152,658 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2015-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
770 |
770 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2015-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
771 |
1,541 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2016-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
775 |
2,316 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2017-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,386 |
4,702 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
EVP, R&D |
• • – |
2017-06-01 |
4 |
A |
$12.06 |
$101,322 |
I/I |
8,400 |
8,400 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2018-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,072 |
6,774 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2019-05-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,478 |
8,252 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2020-05-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,492 |
9,744 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2021-04-15 |
4 |
A |
$0.00 |
$0 |
D/D |
934 |
10,678 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2022-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
40,990 |
765,650 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2022-05-11 |
4 |
A |
$0.00 |
$0 |
D/D |
995 |
11,673 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2023-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
91,036 |
857,861 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2023-05-10 |
4 |
A |
$0.00 |
$0 |
D/D |
1,063 |
12,736 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2024-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
113,586 |
960,072 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2024-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,047 |
13,783 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2018-05-14 |
4 |
AS |
$24.00 |
$201,600 |
I/I |
(8,400) |
0 |
0 |
- |
|
| IQV |
IQVIA Holdings Inc |
Director |
– • – |
2019-12-20 |
4 |
AS |
$151.00 |
$3,090,600 |
D/D |
(20,200) |
8,252 |
0 |
- |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2020-06-03 |
4 |
AS |
$21.83 |
$109,150 |
D/D |
(5,000) |
467,352 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2020-07-01 |
4 |
AS |
$21.83 |
$109,150 |
D/D |
(5,000) |
467,352 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2020-08-06 |
4 |
AS |
$21.83 |
$109,150 |
D/D |
(5,000) |
467,352 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2020-09-01 |
4 |
AS |
$21.83 |
$109,150 |
D/D |
(5,000) |
467,352 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2020-10-07 |
4 |
AS |
$21.83 |
$109,150 |
D/D |
(5,000) |
467,352 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2020-11-04 |
4 |
AS |
$26.00 |
$1,300,000 |
D/D |
(50,000) |
467,352 |
0 |
% |
|
| NTLA |
Intellia Therapeutics, In... |
President and CEO |
• • – |
2020-11-16 |
4 |
AS |
$34.00 |
$680,000 |
D/D |
(20,000) |
467,352 |
0 |
% |
|
75 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
